Navigation Links
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Date:6/28/2008

ing the receptor pharmacology data entitled "Improved Dihydroergotamine (DHE) Pharmacology Following Orally-Inhaled Delivery." In addition to this study, the Company presented five posters relating to the MAP0004 program, including:

-- Newer Acute Migraine Specific Drugs May Provide Improved Sustained Relief and Freedom Over 24 and 48 Hours Post Dosing

-- Chronic Inhalation Toxicological Assessment of Dihydroergotamine in Dogs

-- Assessment of QTc Effect of DHE When Delivered Via the Lung by the Tempo Inhaler

-- MAP0004, an Orally Inhaled Formulation of DHE, Delivers Faster and More Consistent Blood Levels of the Drug Compared to Traditional Oral, Subcutaneous, Intramuscular, and Intranasal Formulations of DHE

-- Systemic Pharmacokinetics of DHE When Delivered Via the Lung to Asthmatics by the Tempo Inhaler

About MAP0004

MAP0004 is a proprietary orally inhaled version of dihydroergotamine, or DHE, intended to treat migraine. In the Company's Phase 2 efficacy study, MAP0004 provided pain relief as early as within ten minutes of dosing, and this relief was sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia. Based on these results, as well as independent research that concludes that patients prefer migraine therapies providing fast onset, pain relief, sustained pain relief and safety, the Company believes that MAP0004 has the potential to be a first-line therapy for migraine patients. Historically, estimated onset of significant pain relief with oral triptans, the class of drugs most often prescribed for treating migraine, occurs between 45 and 90 minutes after dosing. In 2007, triptans generated sales of approximately $2.2 billion in the United States, according to data published by IMS Health.

MAP0004 is designed to be an easy to use, non-invasive, at-home therapy that patients self-administer using the Company's proprietary hand-held
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
6. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
7. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
8. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... According to a new market research report " ... Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, Epilepsy, Ischemia, ... the global Neuromodulation Market is estimated at $3.65 Billion in ... at a CAGR of 11.2% during the forecast period. ... market data T ables and 32 ...
(Date:7/2/2015)... Conn. , July 2, 2015 Numotion,s ... Executive Officer announced that Tamas Feitel has ... Feitel joins Numotion after a highly successful 18 year ... leadership roles driving strategy, profitability, and productivity to result ... most recent position was Chief Financial Officer for GE ...
(Date:7/2/2015)... , June 25, 2015 ... has announced the addition of the ... Immunodiagnostics: Global Challenges, Emerging Technologies, Competitive Landscape" ... 2015 New Frontiers in Clinical Chemistry and ... is a new seven-country strategic analysis of ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, ... Mississippi. The opening is the first sweetFrog store located in Mississippi. The premium frozen ... companies in 2014. , The store, located at 104 Railroad Avenue, New Albany, MS ...
(Date:7/2/2015)... ... July 02, 2015 , ... The ... her introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 on June ... (D-R.I.), this Act seeks to decrease drug overdose – especially of heroin and ...
(Date:7/2/2015)... ... 02, 2015 , ... In 2012, Patrick Achebe realized that the gift of poetry was fully ... to write his first poem, and three years later he was publishing an entire book ... sharing with the world. "I have always believed that the best way to lift yourself ...
(Date:7/2/2015)... GA (PRWEB) , ... July 02, 2015 , ... Global ... newest innovation in compression socks designed for men. , For style that’s quick ... into their daily routine. This is great news for men everywhere because a simple ...
(Date:7/2/2015)... PLAINSBORO, N.J. (PRWEB) , ... July 02, 2015 ... ... ACO and Emerging Healthcare Delivery Coalition met for the late June Web-based ... moves forward with new reimbursement schemes and managing high-risk patients through coordinated care. ...
Breaking Medicine News(10 mins):Health News:sweetfrog Opens First Location in Mississippi 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4
... is Light at the end of the tunnel for HRT ... allowed HRT for treatment of symptoms of menopause, vouching its ... has said that, this would be a reprieve for women ... reported in 2002, which suggested that HRT could increase the ...
... of the pan into the fire itself, the burning problem, ... directives to disclose levels of trans fats in packaged foods, ... trans fat in french fries.// The tests have put French ... more ( 8 grammes as against earlier 6 grams level)trans ...
... of the much dreaded bird flu has been reported from ... The situation is being closely // monitored and is believed ... Agricultural department. ,More than 15, 000 chickens in ... flu virus had died. In response to the above situation, ...
... is launching a nationwide outreach program to improve the ... a follow-up to the Antihypertensive and Lipid-Lowering Treatment to ... in collaboration with the National High Blood Pressure Education ... study had compared the effectiveness of four classes of ...
... of people who suffer from the Ischemic Heart Disease (IHD) ... from // person to person, depending upon whether it ... heart is affected by this medical condition, and where Western ... ,When patients seek medical care for chest pain, ...
... Kenya by the World Bank for HIV/AIDS education and banking ... has been delayed due to some allegations pertaining to corruption ... the Kenyan government, the SAPA/Mail & Guardian reports (SAPA/Mail & ... Health in February 2005 it had failed to distribute $54 ...
Cached Medicine News:Health News:The Decks Cleared For HRT - Safe for Menopause Symptoms 2Health News:Diuretics More Effective In Controlling High Blood Pressure 2
Inquire...
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This is a single-action instrument that features a spring handle....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
Medicine Products: